{"preliminary_commentary":{"by_channel":{"x_thread":6},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":[["trastuzumab","pertuzumab","docetaxel"]],"indication":"advanced non-small cell lung cancer harboring HER2 mutations","name":"R2D2","nct_id":"NCT03845270","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=r2d2-nct03845270. The price is an estimate of verified statements from the commentary indexed so far. Final coverage is set when the report is built. You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_rule":"Never more than quoted: the buyer pays the smaller of price_usd and the price the delivered edition is sold at.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"R2D2","arms":[{"description":"Cycle 1 : D1 : pertuzumab 840 mg, D2 : trastuzumab 8 mg/kg + docetaxel 75 mg/m² Subsequent cycle : D1 : pertuzumab 420 mg + trastuzumab 6 mg/kg + docetaxel 75 mg/m²","label":"pertuzumab + trastuzumab + docetaxel","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2023-12-18","type":"ACTUAL"},"conditions":["Non Small Cell Lung Cancer Metastatic","Non Small Cell Lung Cancer Stage III","HER2 Gene Mutation"],"enrollment":{"count":46,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"pertuzumab + trastuzumab + docetaxel","otherNames":[],"type":"DRUG"}],"last_update":"2023-12-19","lead_sponsor":"Intergroupe Francophone de Cancerologie Thoracique","official_title":"Phase II Trial of Trastuzumab in Combination With Pertuzumab in Pretreated Patients With Non-small Cell Lung Cancer (NSCLC) Harboring a Her2 Mutation and Receiving Docetaxel","overall_status":"COMPLETED","phases":["PHASE2"],"primary_completion_date":{"date":"2021-02-01","type":"ACTUAL"},"primary_outcomes":[{"measure":"Overall Response","timeFrame":"[Time Frame: About 24 months]"}],"references":[{"citation":"Mazieres J, Lafitte C, Ricordel C, Greillier L, Negre E, Zalcman G, Domblides C, Madelaine J, Bennouna J, Mascaux C, Moro-Sibilot D, Pinquie F, Cortot AB, Otto J, Cadranel J, Langlais A, Morin F, Westeel V, Besse B. Combination of Trastuzumab, Pertuzumab, and Docetaxel in Patients With Advanced Non-Small-Cell Lung Cancer Harboring HER2 Mutations: Results From the IFCT-1703 R2D2 Trial. J Clin Oncol. 2022 Mar 1;40(7):719-728. doi: 10.1200/JCO.21.01455. Epub 2022 Jan 24.","pmid":"35073148","type":"RESULT"}],"start_date":{"date":"2019-05-17","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Her2-positive Lung Cancer Treated With Dedicated Drug","url":"https://clinicaltrials.gov/study/NCT03845270"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.2","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/r2d2-nct03845270"}